Biopharma News

Jun 07, 2018
By BioPharm International Editors
The company will provide the first FlexFactory manufacturing platform for TCR T-cell therapy manufacturing.
Jun 05, 2018
By BioPharm International Editors
The agency has approved Mylan’s Fulphila (pegfilgrastim-jmdb) as the first US-approved biosimilar to Amgen’s Neulasta (pegfilgrastim) to reduce infection risk during cancer treatment.
Jun 04, 2018
By BioPharm International Editors
The agency has recommended approval of three biosimilar adalimumab products from Novartis, referencing AbbVie’s Humira, and a biosimilar trastuzumab from Pfizer, referencing Roche’s Herceptin.
Jun 04, 2018
By BioPharm International Editors
EMA has recommended marketing authorization for Aimovig (erenumab), a new treatment for migraine.
May 30, 2018
By BioPharm International Editors
GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM) will support scale-up efforts by DiscGenics for a new cell therapy intended to treat back pain.
May 30, 2018
By BioPharm International Editors
Bayer received conditional approval from the Antitrust Division of the United States Department of Justice to acquire Monsanto in a deal worth $66 billion.
May 29, 2018
By BioPharm International Editors
The European Commission has approved Zessly (infliximab), a biosimilar to Johnson & Johnson’s blockbuster Remicade (infliximab).
May 25, 2018
By BioPharm International Editors
The gene therapy company is expected to invest $55 million in a new manufacturing facility that will produce therapies for rare neurological genetic diseases.
May 23, 2018
By BioPharm International Editors
The new company will develop proprietary RNA-based therapeutics and will provide broad lentiviral development and manufacturing expertise and support.
May 23, 2018
By BioPharm International Editors
WuXi Biologics will build a biologics manufacturing facility in Singapore that will use both fed-batch and continuous perfusion-based single-use bioreactors.
native1_300x100
lorem ipsum